CheckMate 153 trial: how long should nivolumab be taken for?
How to maximize clinical benefits for patients with ALK-positive non-small cell lung cancer
Acquired resistance to third-generation EGFR TKIs in NSCLC
How can durvalumab be used in NSCLC?
Increasing treatment options for NSCLC